US Court Rejects Indivior Stay Appeal On Dr Reddy Injunction Ruling

LONDON (Alliance News) - Indivior PLC said Tuesday a US court has denied the company's stay ...

Alliance News 12 February, 2019 | 8:58AM
Email Form

LONDON (Alliance News) - Indivior PLC said Tuesday a US court has denied the company's stay appeal on a previous ruling vacating an injunction against Indian pharmaceutical company Dr Reddy's Laboratories.

Dr Reddy's has been developing a generic buprenorphine/naloxone treatment, based on Indivior's Suboxone, with Indivior trying to halt development in court. Indivior believes that if Dr Reddy's launches its generic product, it will lose up to 80% of its market share "within a matter of months".

Suboxone is a treatment for opioid addiction, taken either under the tongue, by injection, as an implant, or as a skin patch.

The US Court of Appeals for the Federal Circuit has denied Indivior's motion to stay issuance of the mandate following its ruling vacating the preliminary injunction granted against Dr Reddy's based on Indivior's US patent.

The London-listed opioid addiction treatment drugs maker said it will now file a stay petition on circuit court ruling vacating injunction against Dr Reddy's with the US Supreme Court.

Shares in Indivior were trading 1.6% lower at 105.30 pence each on Tuesday morning.

By Tapan Panchal;

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar Rating
Indivior PLC 44.98 GBX -0.04 -
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.